SAB Biotherapeutics reports Q1 2026 results, enrollment progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. GPRK
6. SCHW
7. TRV
8. TFC
9. NVDA
10. POLYCAB:IN

Go back to SAB Biotherapeutics reports Q1 2026 results, enrollment progress

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 12, 2026 7:30 AM EDT

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc.... More